-
Mashup Score: 0
Renee Bovelle, MD, CSIM; Scott B. Han, OD, FAAO
Source: www.gotoper.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 7ESMO Congress 2023: Registration - 1 year(s) ago
Individual registration is still open
Source: www.esmo.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ESMO23: with all science & education coming out of Madrid, make sure to use the #oncology hashtags to help you drill down & join the conversations relevant to you. Feel free to add any others in the comments below 👇 #OncTwitter https://t.co/0SCjGUa2iN https://t.co/AAkyGfELnp
-
-
Mashup Score: 1Pembrolizumab/Chemotherapy is Approved for Neoadjuvant and Adjuvant Resectable Non-Small Cell Lung Cancer - 1 year(s) ago
The FDA has approved pembrolizumab with platinum-containing chemotherapy for patients with resectable non–small cell lung cancer, in both the neoadjuvant and adjuvant setting.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The FDA has approved pembrolizumab with platinum-containing chemotherapy for patients with resectable non–small cell lung cancer, in both the neoadjuvant and adjuvant settings. #NSCLC #lcsm #oncology #nursing https://t.co/BHX5zi9ZI3
-
-
Mashup Score: 1The Uncommon Cancer: Thyroid Carcinoma - 1 year(s) ago
Thyroid carcinoma is recognized as one of the most uncommon forms of cancer.
Source: www.oncnursingnews.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Thyroid carcinoma is recognized as one of the most uncommon forms of cancer. #oncology #nursing #thyroidcancer https://t.co/HAuWKPRFtJ
-
-
Mashup Score: 2
As Robert A. Winn begins his two-year term as president of the Association of American Cancer Institutes, his presidential initiative of “Inclusive Excellence” aims to increase collaboration among cancer centers, their communities, and other cancer organizations in the United States and abroad. To access this subscriber-only content please log in or renew your subscription.Looking for […]
Source: cancerletter.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@AACI_Cancer/@VCUmassey's @DrRobWinn: "It’s not just what the cancer center needs, it’s what we deliver to our community. And the best way to do that is to have folks at your table." https://t.co/Dcb4q7Tjmz https://t.co/4br53KSrdq
-
-
Mashup Score: 2Sign Up Form: Disability Community Engagement Group | Sign Up Form: Disability Community Engagement Group - 1 year(s) ago
Sign Up Form: Disability Community Engagement Group
Source: hematology.questionpro.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dr. Vogelsang lives w/ a medical disability after an accident & says including people with disabilities in research is critical. ✉️ Sign up for the ASH Disability Community group to receive info about future programming: https://t.co/rtGV2q3PiP #NDEAM #RepresentationMatters https://t.co/W3381r5RsI
-
-
Mashup Score: 1Lung, Kidney, and Neuroendocrine Tumor Cancer Studies Led by Dana-Farber Presented at ESMO Congress 2023 - 1 year(s) ago
Novel treatments, combination therapies, and personalized medicine headline several studies led by Dana-Farber Cancer Institute and presented for the first time at the European Society of Medical Oncology Congress 2023 in Madrid, Spain.
Source: www.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Lung, Kidney, and Neuroendocrine Tumor Cancer Studies Led by Dana-Farber Presented at ESMO Congress 2023 @DanaFarber @myESMO #oncology #ESMO2023 https://t.co/1CJEa6Y5F4
-
-
Mashup Score: 0Do Low- and Moderate-Grade Adverse Events Affect Rates of Treatment Discontinuation in CLL - The ASCO Post - 1 year(s) ago
In an analysis from the phase III ECOG/ACRIN E1912 trial in chronic lymphocytic leukemia (CLL) published in the Journal of Clinical Oncology, O’Connell et al found that grade 1 and 2 adverse events were significant contributors to patient-reported side-effects bother, with grade 2 events being associated with increased odds of treatment discontinuation. In the trial, patients with CLL received 28-day cycles of continuous ibrutinib or six 28-day cycles of chemoimmunotherapy with fludarabine, cyclophosphami
Source: ascopost.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Do Low- and Moderate-Grade Adverse Events Affect Rates of Treatment Discontinuation in CLL? https://t.co/D36te8eAzJ #leusm #hematology
-
-
Mashup Score: 1
Exercise, nutrition, and weight management guidelines are widely recognized; however, no recommendations have specifically focused on improving body composition in breast cancer patients. This review…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Exercise, nutrition, and weight management guidelines are widely recognized; however, no recommendations have specifically focused on improving body composition in #BreastCancer patients. https://t.co/nck1s0wH9E #OpenAccess #BreastCancerAwarenessMonth https://t.co/92f0V60jRl
-
-
Mashup Score: 1
Published: October 16, 2023Updated: October 17, 2023Written by: Rob LevyMedically Reviewed By: Jia Luo, MDWhat is NUT carcinoma? NUT carcinoma, formerly known as NUT-midline carcinoma, is a rare but very aggressive cancer that can develop anywhere in the body but usually starts in the head, neck, and lungs. It’s a squamous cell cancer — meaning … Read more
Source: blog.dana-farber.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Dana-Farber and its allied hospitals have one of the only clinical trial programs in the country dedicated to finding better treatments for NUT carcinoma. Learn more: https://t.co/IpunBZV2tu #NUTcarcinoma @Jia_Luo https://t.co/vqX3SQMj2h
-
Individualizing Care in Allergic Conjunctivitis/Understanding the Patient’s Perspective in Alleviating Disease Burden. Register here: https://t.co/l66brEOw3T #PER #PEROnline #PEROnlineActivities https://t.co/VNhV50Jce1